Investor presentation

RNS Number : 4507P

Genedrive PLC

10 June 2020

 

genedrive plc

("genedrive" or the "Company")

Investor presentation

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, is pleased to announce that David Budd, Chief Executive Officer, will be presenting at an investor webinar being hosted jointly by Turner Pope Investments (TPI) Ltd and Vox Markets.

The event will be held on Friday, 12 June 2020 at 2pm. Please register your interest at  https://voxmarkets.brand.live/c/genedrive-plc .

genedrive plc	[phone]
David Budd: CEO / Matthew Fowler: CFO
Peel Hunt LLP (Nominated Adviser and Joint Broker)	[phone]
James Steel / Oliver Jackson
finnCap (Joint Broker)	[phone]
Geoff Nash / Kate Bannatyne / Alice Lane
Walbrook PR Ltd (Media & Investor Relations)	[phone] or [e-mail]
Paul McManus / Anna Dunphy	[phone] / [phone]

About genedrive plc ( http://www.genedriveplc.com )

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently launched a high throughput SARS-CoV-2 assay and has a Genedrive® Point of Care version of the assay in development, both based on Genedrive® PCR chemistry.

 

END

 

 

NRAFLFIRRFIAIII